GoodRx Target of Unusually High Options Trading (NASDAQ:GDRX)

GoodRx Holdings, Inc. (NASDAQ:GDRX) was the recipient of some unusual options trading on Monday. Stock investors purchased 8,411 call options on the stock. This represents an increase of approximately 1,884% compared to the typical daily volume of 424 call options.

GoodRx Stock Up 0.6 %

Shares of NASDAQ GDRX opened at $4.84 on Tuesday. GoodRx has a 12-month low of $4.09 and a 12-month high of $9.26. The company has a market cap of $1.84 billion, a P/E ratio of -161.33, a P/E/G ratio of 2.46 and a beta of 1.28. The company has a current ratio of 5.48, a quick ratio of 5.48 and a debt-to-equity ratio of 0.70. The stock has a fifty day moving average price of $4.67 and a 200 day moving average price of $5.79.

Analysts Set New Price Targets

Several equities analysts have issued reports on GDRX shares. Mizuho started coverage on GoodRx in a research report on Wednesday, December 4th. They set a “neutral” rating and a $5.00 target price on the stock. Citigroup dropped their target price on GoodRx from $7.00 to $6.25 and set a “buy” rating on the stock in a research report on Friday, January 10th. Morgan Stanley dropped their target price on GoodRx from $7.00 to $6.00 and set an “equal weight” rating on the stock in a research report on Tuesday, December 17th. Barclays dropped their target price on GoodRx from $10.00 to $6.00 and set an “overweight” rating on the stock in a research report on Monday, November 11th. Finally, KeyCorp dropped their target price on GoodRx from $7.00 to $6.00 and set an “overweight” rating on the stock in a research report on Wednesday, January 8th. Five research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $8.38.

Institutional Trading of GoodRx

Several large investors have recently modified their holdings of the business. Point72 Asset Management L.P. bought a new position in shares of GoodRx during the third quarter worth about $11,295,000. Clearbridge Investments LLC bought a new position in GoodRx in the fourth quarter worth about $5,863,000. Rubric Capital Management LP lifted its holdings in GoodRx by 25.2% in the third quarter. Rubric Capital Management LP now owns 4,680,028 shares of the company’s stock worth $32,479,000 after acquiring an additional 943,226 shares during the last quarter. Franklin Resources Inc. bought a new position in GoodRx in the third quarter worth about $5,675,000. Finally, Jacobs Levy Equity Management Inc. lifted its holdings in GoodRx by 303.3% in the fourth quarter. Jacobs Levy Equity Management Inc. now owns 1,061,461 shares of the company’s stock worth $4,936,000 after acquiring an additional 798,261 shares during the last quarter. 63.77% of the stock is currently owned by institutional investors and hedge funds.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.